Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Expands By 240.4%

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totalling 623,300 shares, a growth of 240.4% from the July 31st total of 183,100 shares. Approximately 11.9% of the shares of the company are sold short. Based on an average daily volume of 6,760,000 shares, the short-interest ratio is presently 0.1 days.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX traded down $0.97 during trading on Wednesday, hitting $5.00. 4,935,894 shares of the company were exchanged, compared to its average volume of 2,722,628. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The firm’s fifty day moving average price is $3.25 and its 200 day moving average price is $2.35.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share for the quarter, topping the consensus estimate of ($2.57) by $0.58. The company had revenue of $0.30 million for the quarter. During the same quarter in the prior year, the firm earned ($3.30) EPS. Analysts forecast that GeoVax Labs will post -7.41 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC bought a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 6.09% of the company’s stock.

Wall Street Analyst Weigh In

GOVX has been the topic of a number of research reports. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research note on Monday, August 12th. Roth Capital raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 16th. Roth Mkm initiated coverage on GeoVax Labs in a research note on Tuesday, July 16th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Noble Financial increased their price target on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, August 19th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $12.67.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.